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(57) 	 ABSTRACT 
The present invention provides a method of forming a blood-
clot microvalve by heating blood in a capillary tube of a 
microfluidic device. Also described are methods of modulat-
ing liquid flow in a capillary tube by forming and removing a 
blood-clot microvalve. 
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THERMAL BLOOD CLOT FORMATION AND 
	
having a threshold differential pressure of from about 0 psi to 
USE IN MICROFLUIDIC DEVICE VALUING 	 about 100 psi, thus modulating the liquid flow through the 
APPLICATIONS 	 capillary tube. 
CROSS-REFERENCES TO RELATED 	 5 	 BRIEF DESCRIPTION OF THE DRAWINGS 
APPLICATIONS 
This application claims priority to U.S. Provisional 
Applictaion No. 61/382,867, filed Sep. 14, 2010. 
10 
STATEMENT AS TO RIGHTS TO INVENTIONS 
MADE UNDER FEDERALLY SPONSORED 
RESEARCH AND DEVELOPMENT 
The invention described herein was made in the perfor- 15 
mance of work under a NASA contract NCC 9-58, subcon-
tract TD01301, and is subject to the provisions of Public Law 
96-517 (35 USC 202) in which the Contractor has elected to 
retain title. 
20 
BACKGROUND OF THE INVENTION 
Microfluidic technology has been studied extensively to 
develop low-cost lab-on-a-chip devices. These devices often 
require the use of simple, reliable valves to facilitate their 25 
operations. Many MEMS-based valving principles, such as 
utilizing magnetostatics, electrostatics, pneumatics or ther-
mal actuation of movable membranes, have been thoroughly 
studied, but the fabrication and/or the operation of these 
valves could still be complicated. Therefore, valves with 30 
simple structure such as those operated by using phase-
change materials orrheological materials are of great interest. 
Unfortunately, there is still a lack of simple microvalves 
especially for on-chip blood analysis. Interestingly, blood is a 
fluid that can coagulate under the right conditions, and this 35 
coagulation process may provide a natural valving mecha-
nism that has not been well explored in microfluidics. In 
blood vessels, solid blood coagulum can be formed through 
biological clotting process to stop bleeding. Similarly, others 
methods can be used to trigger the blood coagulation. For 40 
example, thermal coagulation uses heating to introduce the 
blood clogging, which is mainly a process of protein dena-
turation and cross linking. This coagulation property of blood 
provides an interesting alternative to traditional valving 
mechanisms. A valve using blood coagulation as the actua- 45 
tion method needs no extra material other than the blood 
sample itself, which is readily available in devices targeting 
for blood analysis. Surprisingly, the present invention meets 
this and other needs. 
50 
BRIEF SUMMARY OF THE INVENTION 
FIG. 1 shows an illustration of the operation principle of 
the blood clogging valve. The fluidic channel is normally 
open for blood to flow through. To close the valve, the blood 
inside the valve zone is locally heated, forming a solid clog to 
physical block the channel. 
FIG. 2 shows a schematic of the back pressure measure-
ment configuration and a picture of a capillary tube with 
blood clog formed inside. 
FIG. 3 shows a picture (Left) of the PDMS device for the 
pressure test of clogging in microfluidic channels, and an 
illustration (Right) of the test operation procedure. The 
dashed area marks the main valve zone. 
FIG. 4 shows the measured maximum back pressure of the 
blood clog formed in capillary tubes vs. heating time with 
respect to different heating temperatures. 
FIG. 5 shows microscopy pictures of the blood in a PDMS 
channel before (Left) and after (Right) clogging. The inset 
shows the zoom-in picture of the outlined area (100 µm chan-
nel height). 
FIG. 6 shows a summary of the measured results of maxi-
mum back pressure vs. 
clog sizes, including results from both capillary tubes and 
PDMS devices. Same heating condition (80° C., 30 min) was 
used for the clogging. For the results from PDMS devices, the 
pressure of 50 psig or higher means the PDMS delaminated 
from the glass substrate before the clog failing the test. 
FIG. 7 shows microscopy pictures of the blood in a PDMS 
channel before (Left) and after (Right) laser-induced clog-
ging. The outline of the clog site is defined by the size of the 
laser spot (40 µm diameter), which is slightly wider than the 
fluidic channel (36 µm wide). 
FIG. 8 shows an illustration of implementing the laser-
induced clogging valve for sample volume control in a 
microfluidic cytometer. The sample chamber has four fluidic 
ports. The top port connects to an upstreampump. The bottom 
port connects to a narrowed channel, which serves as a cytom-
eter flowcell. The left and right channels are blood loading 
ports as well as the sites of the clogging valve. 
FIG. 9 shows microscopy pictures of the PDMS device and 
the operation of implementing the laser-induced clogging 
valve in a microfluidic cytometer. (Left) Blood was loaded 
into the sample chamber and sealed inside by two clogging 
valves. (Right) The sample was pushed out by a syringe pump 
for downstream analysis in a cytometer flowcell. 
DETAILED DESCRIPTION OF THE INVENTION 
In one embodiment, the present invention provides a 
method of forming a blood-clot microvalve in a capillary tube 
or microchannel of a microfluidic device. The method 
includes heating blood in the capillary tube or microchannel 
at a temperature of from about 50° C. to about 100° C. for a 
sufficient period of time, such that a solid blood coagulum is 
formed having a threshold differential pressure of from about 
0 psi to about 100 psi. Thus, the method forms the blood-clot 
microvalve. 
In other embodiments, the present invention provide a 
method of modulating liquid flow through a capillary tube or 
microchannel of a microfluidic device. The method includes 
heating blood in the capillary tube or microchannel at a tem-
perature of from about 50° C. to about 100° C. for a sufficient 
period of time, such that a solid blood coagulum is formed 
I. General 
55 The invention is a method of forming a microvalve in a 
capillary tube of a microfluidic device, where the microvalve 
is prepared from blood by heating the blood at a sufficiently 
high temperature to form a solid blood coagulum that blocks 
the flow of blood in the capillary tube. The heating can be 
60 localized to one segment of the capillary tube, or can be to the 
entire microfluidic device. 
Without being bound to any one theory, blood thermal 
coagulation is a complex phenomenon that encompasses sev- 
eral processes including deformation and rupture of erythro- 
65 cytes, protein denaturation, aggregation, and blood gelation. 
Under a heating temperature of 45° C., the normal disc- 
shaped erythrocytes starts to transform into the spherocytes, 
US 8,845,979 B2 
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and substantial fragmentation of erythrocytes occurs after the 	 embodiments, the temperature can be from about 70° C. to 
heating temperature reaches 60° C. Meanwhile, the protein 	 about 80'C. In some other embodiments, the temperature can 
denaturation is a continuous process which depends on both 
	
be about 75° C. 
the heating temperature and heating duration. For example, 	 The blood-clot microvalve formed can be stable to any 
an elongated heating of 1 hour under a heating temperature of 5 suitable threshold differential pressure. For example, the 
60° C. is sufficient to convert the liquid blood into a solid gel 	 threshold differential pressure canbe greater than 0 psi, 5, 10, 
matrix, and a rapid heating of 1 minute under a heating 	 20, 30, 40, 50 psi, or greater. The threshold differential pres- 
temperature of 85° C. can also reach the coagulation. 	 sure canbe from about 0 psi to about 100 psi, or from about 25 
Thermal coagulation of blood is a result of intramolecular 	 psi to about 100 psi, or from about 40 psi to about 100 psi, or 
hydration of serum proteins, primarily in the albumin frac-  io from about 10 psi to about 75 psi, or from about 25 psi to 
tion. Because formation of the blood coagulum is thermally 	 about 75 psi, or from about 30 psi to about 50 psi. In some 
driven, the presence of chemical anticoagulants does not 	 embodiments, the threshold differential pressure can be from 
impair the thermal formation of the blood coagulum. See Am. 	 0 psi to about 100 psi. In other embodiments, the threshold 
J. of Medicine 1950, 745. 	 differential pressure can be from about 10 psi to about 75 psi. 
II. Definitions 	 15 In some other embodiments, the threshold differential pres- 
"Blood-clot microvalve" refers to a microvalve in a capil- 	 sure can be from about 30 psi to about 50 psi. In still other 
lary tube formed by a thermally induced blood clot. 	 embodiments, the threshold differential pressure can be about 
"Capillary tube" refers to a tube up to several centimeters 	 40 psi. 
in length having a width and heighth on the scale of hundreds 	 The heating canbe for any suitable period of time, with less 
of microns, or smaller, for transporting fluid. The capillary 20 time typically needed at higher temperatures to form the 
tubes can be in a microfluidic device. "Segment' refers to a 	 solid-blood coagulum having a certain threshold differential 
portion of the capillary tube, and includes adjacent and non- 	 pressure. For example, the heating can be for a period of at 
adjacent segmetns. A capillary tube can include any number 	 least about 1 second, or 10, 30 or about 60 seconds. The 
of segments. The segments can be any suitable length and can 	 heating can also be for a period of at least about 1 minute, or 
all have the same length or different lengths. 	 25 2, 3, 4, 5, 6, 7, 8, 9 or about 10 minutes. The heating can also 
"Blood" refers to whole blood and any combination of the 	 be for a period of from about 1 second to about 10 minutes, or 
constituents of blood, such as cells (erythrocytes, leukocytes, 	 about 1 minute to about 10 minutes, or about 2 minutes to 
thrombocytes or platelets), red blood cells, white blood cells, 	 about 5 minutes. The heating can also be for a period of about 
plasma, serum albumin, blood-clotting factors, immunoglo- 	 1 minute, or 2, 3, 4, 5, 6, 7, 8, 9 or about 10 minutes. In some 
bulins, lipoproteins, and various other proteins and electro-  30 embodiments, the heating can be for a period of about 1 
lytes. Blood can be from any suitable animal, such as a mam- 	 second to about 10 minutes. In other embodiments, the heat- 
mal including a human. 	 ing can be for a period of about 2 minutes to about 5 minutes. 
"Solid blood coagulum" refers to a coagulated mass 	 In some other embodiments, the heating can be for a period of 
formed from blood. 	 about 3 minutes. 
"Threshold differential pressure" refers to the minimum 35 	 Any combination of temperature and time is useful for 
pressure differential across the solid blood coagulum. 	 forming the blood-clot microvalves of the present invention. 
`Anticoagulant' refers to a substance or compound that 	 For example, the heating can be for a period of about 10 
prevents coagulation, such as coagulation of blood. Suitable 	 seconds at a temperature of about 90° C., or for a period of 
anticoagulants include, but are not limited to, ethylenedi- 	 about 3 minutes at about 75° C. In some embodiments, the 
amine tetraacetic acid (EDTA). 	 4o heating is at 75° C. for a period of about 3 minutes. 
"Modulating liquid flow" refers to increasing or decreasing 	 The blood used in the method of the present invention can 
the rate of flow of a liquid in a capillary tube. 	 be any suitable blood. The blood canbe from any animal. The 
III. Forming a Blood-Clot Microvalve 	 blood is preferably from a mammal, such as primates (e.g., 
The present invention provides methods of forming a 	 humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, 
microvalve in a capillary tube of a microfluidic device using 45 mice and the like. Blood can refer to whole blood or any 
blood. Heating the blood above a certain temperature causes 	 components of blood, such as serum, plasma, red blood cells 
the blood to thermally coagulate and in certain instances, in 	 (RBCs), and white blood cells (WBCs). The blood can also 
the presence or the absence of a chemical coagulant. Thus, 	 include synthetic additives such as an anticoagulant or other 
heating the blood in the capillary tube forms the blood-clot 	 blood stabilizer or preservative. Anticoagulants that can be 
microvalve. 	 50 present in the blood include, but are not limited to, ethylene- 
In some embodiments, the present invention provides a 	 diaminetetraacetic acid (EDTA), coumadin, warfarin, hep- 
method of forming a blood-clot microvalve in a capillary tube 	 arin, citrate, or oxalate. 
or microchannel of a microfluidic device. The method 
	
In some embodiments, the blood can be human blood. In 
includes heating blood in the capillary tube or microchannel 	 other embodiments, the blood can be plasma. In some other 
at a temperature of from about 50° C. to about 100° C. for a 55 embodiments, the blood can include an anticoagulant. In still 
sufficient period of time, such that a solid blood coagulum is 	 other embodiments, the blood can include ethylenediamine- 
formed having a threshold differential pressure of from about 	 tetraacetic acid (EDTA). 
0 psi to about 100 psi. Thus, the method forms the blood-clot 	 The heating can be accomplished by any suitable means 
microvalve. 	 known in the art. For example, the heating can be accom- 
Any microfluidic device is suitable in the inventive 60 plished by systemic heating using a water bath or other fluid 
method. 	 bath, or heating only a portion of the capillary tubes such as 
The heating can be performed at any suitable temperature. 	 with a laser or integrated ohmic heater. In some embodiments, 
For example, the temperature can be from 40° C. to 100° C., 	 the heating is performed using a laser. 
such as 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100° C. 	 The basic principle of the laser induce heating is that the 
The temperature can be from 50° C. to 100° C., or 60° C. to 65 hemoglobin in erythrocytes has good absorbance towards the 
90° C., or 70° C. to 80° C. In some embodiments, the tem- 	 light in visible wavelength range, and the absorbed energy is 
perature can be from about 60° C. to about 90° C. In other 	 then converted into heat, rising the temperature of the blood 
US 8,845,979 B2 
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sample. Therefore, when a laser of certain intensity is used, 
sufficient heating can be generated and leads to the thermal 
coagulation. In this study, a 488 mn continuous-wave laser is 
employed for this purpose. The laser beam is focused into a 
confined area, the size of which is slightly larger than the 
valve zone. By optimizing the intensity and duration of the 
laser, blood clogging can be induced inside the valve zone 
with minimized excessive heating. 
The heating of the capillary tube can involve heating the 
entire capillary tube and microfluidic device, or heating one 
or more segments of the capillary tube. The capillary tube can 
include any suitable number of segments, such as 2, 3, 4, 5, 6, 
7, 8, 9, 10 or more. When the capillary tube includes at least 
2 segments, any number of the segments can be heated. For 
example, when the capillary tube includes 3 segments, 2 of 
the segments can be separately heated. When the capillary 
tube includes 5 segments, 3 of the segments can be separately 
heated. The heated segments can be adjacent to one another or 
separated by non-heated segments. 
The blood-clot microvalves formed in the various seg-
ments of a single capillary tube or in different capillary tubes 
of a microfluidic device can have the same or different thresh-
old differential pressures. 
In some embodiments, the capillary tube includes at least 25 
two segments, such that only one segment is heated to form 
the blood-clot microvalve in the heated segment. In other 
embodiments, the capillary tube includes at least three seg-
ments, such that at least two non-adjacent segments are 
heated to form the blood-clot microvalve in each of the heated 30 
segments. 
The capillary tube can be any suitable length and width or 
diameter. For example, the capillary tube can have a width of 
from about 1 µm and about 10,000 µm, or about 10 µm to 35 
about 1000 µm, or from about 10 µm to about 500 µm. The 
length of the capillary tube can be from about 100 µm to about 
10 centimeters, or from about 100 µm to about 1 cm, or from 
500 µm to about 5 mm. 
In some embodiments, the method of the present invention 40 
includes heating human blood, wherein the human blood 
includes ethylenediaminetetraacetic acid (EDTA), in the cap-
illary tube at a temperature of about 75° C. for a period of 
about 3 minutes, such that the solid blood coagulum formed 
has a threshold differential pressure of about 40 psi, thus 45 
forming the blood-clot microvalve. 
IV. Modulating Liquid Flow 
The present invention also provides methods of modulat-
ing blood flow in a capillary tube by forming a reversible 
blood-clot microvalve, and then, optionally, removing the 50 
blood-clot microvalve. 
In some embodiments, the present invention provide a 
method of modulating liquid flow through a capillary tube or 
microchannel of a microfluidic device. The method includes 
heating blood in the capillary tube or microchannel at a tern- 55 
perature of from about 50° C. to about 100° C. for a sufficient 
period of time, such that a solid blood coagulum is formed 
having a threshold differential pressure of from about 0 psi to 
about 100 psi, thus modulating the liquid flow through the 
capillary tube. In other embodiments, the method includes 60 
heating human blood, wherein the human blood includes 
ethylenediaminetetraacetic acid (EDTA), in the capillary tube 
at a temperature of about 75° C. for a period of about 3 
minutes, such that the solid blood coagulum is formed having 
a threshold differential pressure of about 40 psi. 65 
Modulating the liquid flow also includes increasing the 
liquid flow in the capillary tube. This can be accomplished by 
Human whole blood from healthy donors was used. Blood 
samples were purchased from Hemacare Corp. (CA, USA) 
and tested within 48 hours after drawing. The samples, after a 
routine analysis with respect to the concentration of erythro-
cytes, hemoglobin and other standard blood parameters of 
interest, were kept in the standard 5 ml purple tubes with 
Ethylenediaminetetraacetic acid (EDTA) coating and stored 
in 4° C. refrigerator before experiments. 
The thermal coagulation was studied using glass capillary 
tubes (0.38 mm diameter, 10 µL Accu-Fill Micropet). For 
each test, the capillary tube was loaded with 2 µL, of blood 
and heated in a water bath to form the clog. The temperature 
of the water bath was constantly monitored with a thermom-
eter. The tube was then connected to the test configuration 
shown in FIG. 2 by epoxy, and the mechanical strength of the 
blood clog, in terms of the back pressure it could withstand, 
was measured. An increasing air pressure with a ramp rate of 
1 psig/5 sec was applied continuously on one end of the clog. 
The maximum back pressure was recorded as the pressure 
before either the clog bursting or air leakage observed by 
sealing the other end of the tube with a water drop. A wide 
range of heating temperatures (60, 65, 70, 75, 80, 85, 90° C.) 
and variable heating times (0, 1/6, '/2, 1, 2, 3, 5 and 10 min) 
were evaluated. 
Additional experiments were performed with PDMS 
devices fabricated using a standard one-layer PDMS/glass 
bonding process. First, PDMS (Sylgard, 10:1 ratio of base 
and curing agent) was poured onto a SUS mold to form the 
microfluidic channels. After partial curing in an oven at 80'C. 
for 30 minutes, the PDMS sheet was peeled off and cut into 
individual devices. The fluidic ports were made by the punch-
ing of a syringe needle. Then the PDMS block was bonded to 
a cleaned glass slide and further cured at 100° C. for 2 hours 
to form the final device. 
FIG.1 illustrates the basic principle of utilizing this coagu-
lation property as an open-to-close valve. The valve is nor-
mally open, allowing the blood sample to flow freely through 
the microfluidic channel. To actuate the valve, the valving 
zone is locally heated to transform the blood inside into a 
solidified coagulum. The blood clog hence seals the entire 
cross section of the fluidic channel and physically stems the 
flow, which realizes a one-time use open-to-close valve. The 
structure of this valve is simple, but extremely elegant. 
For local thermal coagulation of the blood inside the valve 
zone, a focused laser beam is used to induce the local blood 
heating. Laser induced coagulation has been used in eye 
6 
removing the blood-clot microvalve formed in the methods 
described above. The blood-clot microvalve that is formed in 
the above methods is susceptible to sustained high tempera-
tures which breakdown the bonds formed during the initial 
5 formation of the solidblood coagulum. Temperatures suitable 
for removal of the solid blood coagulum are from about 75' C. 
to about 100° C., or from about 80, 85, 90, or 95° C. to about 
100° C. The temperature for removal of the solid blood 
coagulum can be about 85'C., or 86, 87, 88, 89, 90, 91, 92, 93, 
10 94, 95, 96, 97, 98, 99 or about 100° C. In some embodiments, 
the method also includes heating the solid blood coagulum at 
a temperature of at least 90° C. to remove the solid blood 
coagulum. 
15 	 EXAMPLES 
Example 1 
20 	 Formation of Blood-Clot Microvalve 
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surgeries to finely cauterize ocular blood vessels. A similar 
procedure is used here to create blood clog in microfluidic 
channels. 
FIG. 3 shows the PDMS device with the microfluidic chan-
nels for testing the back pressure that the blood clog can hold. 
The device consists of a main valve zone and four fluidic 
ports. The size of the clog is mainly decided by the dimension 
of the valve zone. Two fluidic ports are used for loading blood, 
while the other two are used to applied an elevated air pres-
sure on the two ends of the valve zone. After filled with blood, 
the device was heated with the glass side contacting the 
heated water bath to induce the blood thermal coagulation. 
Metal tubes were inserted into the PDMS ports to provide 
world-to-chip connections for the compressed air and then 
the back pressure was tested by the same configuration as 
shown in FIG. 2. 
The laser platform used in these experiments for laser 
induced thermal coagulation included the following: An opti-
cal microscope (Axioskop 50, Zeiss) was modified to accom-
modate a 20 mW, 488 nun solid-state laser by replacing the 
mounted camera with a optical fiber delivering the laser. The 
laser beam was first passed through a beam splitter (70% 
transmission) and then focused by a 20x objective lens into a 
40 µm diameter area. The beam splitter could be adjusted 
between two positions. With the splitter slid in, the laser was 
shielded and only the bright field image was captured by the 
eyepiece camera. With the splitter pulled out, the laser was 
allowed to pass through for heating the blood sample, while 
both the bright field image and the image of the laser spot 
were captured. A 488 nun high pass filter was used to prevent 
most of the reflected laser from entering the camera. The 
device was mounted on a sample stage, which supported the 
z-axis focusing, and both the x-axis and y-axis tuning of the 
device position. The alignment between the clogging valve 
and the laser illumination was monitored through the live 
video of the camera. 
FIG. 4 shows the results of the maximum back pressure 
versus heating time under different heating temperatures, 
which is measured from the clog in capillary tubes. For a 
heating temperature of 60° C., the blood remains in liquid 
form after a 5 min heating period. After 10 min heating, a 
gel-like clog was formed but could only withstand a back 
pressure of 10 psig. For temperatures between 65° C. and 90° 
C., the coagulation occurs with shorter heating times, as 
expected from the continuous protein denaturation process. 
For each temperature, the withstood back pressure first rises 
with increasing heating time before reaching a relatively 
stable range, where the clog formed at 90° C. withstands a 
pressure (30-40 psig) lower than the pressure (50-70 psig) of 
the clogs formed at temperatures between 65° C. and 85° C. 
This observation can be attributed to the excessive dehydra-
tion of the sample under the 90° C. heating. In general, clog 
formed under a 70-90° C., 1-3 min heating withstands a back 
pressure of 30 psig or higher. 
FIG. 5 shows the microscopic pictures of the blood clog 
formed in the PDMS channel. At beginning, the blood is in 
liquid form, where the individual erythrocyte cells and the 
surrounding plasma are clearly distinguishable. After an 80° 
C., 3 min heating, a uniformly distributed coagulum is 
formed, blocking the whole cross section of the fluidic chan-
nel. Two valve designs with same channel height and width 
but different channel length, are tested under this heating 
condition, and the results, as summarized in Table 1 (results 
show the mean value of three tests), show that the clogged 
valve withstands a back pressure of 35 psig or higher. 
10 
FIG. 6 summarizes the results of valve closed ("clogged") 
formed in the capillary tube and in the PDMS channel, and the 
minimum back pressures withstood were plotted versus the 
clog size. It shows that clogs formed in smaller tubes/chan- 
15 nels withstand higher minimum back pressures, which sug-
gests the scaling advantage of this approach for microfluidics. 
FIG. 7 shows the microscopic pictures of localized valving 
("clogging") introduced by the laser illumination. The 
microfluidic channel is 30 µm high and 36 µm wide, which is 
20 pre-loaded with human whole blood. The laser spot (40 M in 
diameter) was aligned along the center of the fluidic channel. 
After a 1 min illumination, the section of the blood under-
neath the laser spot was locally solidified, and seals the entire 
cross section of the channel. In the picture, the clog shows a 
25 darker color than the surrounding blood sample. This local-
ized clog was tested by the same configuration as shown in 
FIG. 2, and it withstands a back pressure of 26±4 psig, suffi-
cient for most low-pressure microfluidic applications. 
FIG. 8 illustrates the implementation of this clogging valve 
30 in a microfluidic cytometer we developed. The sample cham-
ber has four fluidic ports. The upper port connecting to the 
upstream pump and the lower port connecting to downstream 
analysis are initially closed, so that the blood sample can be 
loaded into the chamber through the two side ports. After 
35 filling up the whole chamber, both of the two loading ports are 
filled with blood and can be sealed by the laser-induced 
clogging. Then the upstream pump starts to push the sample 
for downstream analysis, and the delivered sample volume is 
controlled by the dimensions of the chamber. 
40 A PDMS device is used to demonstrate this operation. As 
shown in FIG. 9, blood samples are firstly sealed inside the 
chamber by two clogging valves and then pushed out for 
downstream analysis, where a volume of 0.1 ltL, blood was 
successfully delivered. 
45 	 Although the foregoing invention has been described in 
some detail by way of illustration and example for purposes 
of clarity of understanding, one of skill in the art will appre-
ciate that certain changes and modifications may be practiced 
within the scope of the appended claims. In addition, each 
50 reference provided herein is incorporated by reference in its 
entirety to the same extent as if each reference was individu-
ally incorporated by reference. Where a conflict exists 
between the instant application and a reference provided 
herein, the instant application shall dominate. 
55 	 What is claimed is: 
1. A method of forming a blood-clot microvalve in a 
microfluidic device comprising heating a blood or blood 
plasma sample in a capillary tube or microchannel of the 
microfluidic device at a temperature of from about 50° C. to 
6o about 100° C. for a sufficient period of time, such that a solid 
blood coagulum is formed in the capillary tube or microchan-
nel having a threshold differential pressure of greater than 0 
psi to about 100 psi, thus forming the blood-clot microvalve. 
2. The method of claim 1, wherein the temperature is from 
65 about 60° C. to about 90° C. 
3. The method of claim 1, wherein the temperature is from 
about 70° C. to about 80° C. 
8 
TABLE 1 
Measured maximum back pressure of the blood clog from two 
geometry designs (W: width, H: height, L: length) 
5 	 Dimension (µm) 
Design 	 W x H x L 	 Pressure (psig) 
A 	 100 x 50 x 800 	 35 ± 8 
B 	 101 x 50 x 1600 	 >50, PDMS delaminated 
US 8,845,979 B2 
9 
4. The method of claim 1, wherein the temperature is about 
75° C. 
5. The method of claim 1, wherein the solid blood coagu-
lum has a threshold differential pressure of from about 10 psi 
to about 75 psi. 
6. The method of claim 1, wherein the solid blood coagu-
lum has a threshold differential pressure of from about 30 psi 
to about 50 psi. 
7. The method of claim 1, wherein the solid blood coagu-
lum has a threshold differential pressure of about 40 psi. 
8. The method of claim 1, wherein the blood is heated for 
a period of about 2 to about 5 minutes. 
9. The method of claim 1, wherein the blood is heated for 
a period of about 3 minutes. 
10. The method of claim 1, wherein the blood is heated at 
about 75° C. for about 3 minutes. 
11. Themethod of claim 1, wherein theblood comprises an 
anticoagulant. 
12. The method of claim 1, wherein the blood comprises 
ethylenediaminetetraacetic acid (EDTA). 
13. The method of claim 1, wherein the blood is human 
blood. 
14. The method of claim 13, wherein the human blood 
comprises ethylenediaminetetraacetic acid (EDTA), and the 
capillary tube is heated at a temperature of about 75° C. for a 
period of about 3 minutes, such that the solid blood coagulum 
formed has a threshold differential pressure of about 40 psi. 
15. The method of claim 1, wherein the sample is blood 
plasma. 
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16. The method of claim 1, wherein the capillary tube 
comprises at least two segments, such that only one segment 
is heated to form the blood-clot microvalve in the heated 
segment. 
5 	 17. The method of claim 1, wherein the capillary tube 
comprises at least three segments, such that at least two non-
adjacent segments are heated to form a blood-clot microvalve 
in each of the heated segments. 
18. A method of modulating liquid flow through a microf-
luidic device comprising heating a blood or blood plasma 
sample in a capillary tube or microchannel of the microfluidic 
device at a temperature of from about 50° C. to about 100° C. 
for a sufficient period of time to form a solid blood coagulum, 
15 such that the solid blood coagulum forms a microvalve in the 
capillary tube or microchannel having a threshold differential 
pressure of greater than 0 psi to about 100 psi, thus modulat-
ing the liquid flow through the microfluidic device. 
19. The method of claim 18, wherein the blood is human 
20 blood and comprises ethylenediaminetetraacetic acid 
(EDTA), and the capillary tube is heated at a temperature of 
about 75° C. for a period of about 3 minutes, such that the 
solid blood coagulum is formed having a threshold differen-
tial pressure of about 40 psi. 
25 	 20. The method of claim 19, further comprising heating the 
solid blood coagulum at a temperature of at least 90° C. to 
remove the solid blood coagulum. 
